SubscribeThe Agency has a proven track record of generating novel ideas, and an active patenting policy leading to new products and platform technologies.
It also has a successful history of out-licensing and partnership deals which have enabled such products and technologies to reach the market.
Research Partnerships
Entry points can vary from early stage research to clinical development candidates, with deals structured to reflect these different stages.
Exclusivity
The nature of the organisation's research base, centred on pathogenic organisms, healthcare products and impartial expertise, means that each of the partnership opportunities offered is unique. In addition the depth of know-how within the organisation ensures that our partners have access to a knowledge base and expert opinion second to none.
Added Assurance
We are an independent public sector organisation with over 50 years of experience in developing biological products. This track record provides the added reassurance of an established organisation which is committed to developing the science base into the 21st century.
The Agency's Centre at Porton Down has the benefits of being a secure location, able to undertake sensitive work, in a pleasant area of southern England with good communication links and access to a skilled workforce.
Development Partnerships
Many organisations have recognised the outstanding range of expertise within the Agency.
Here are some examples:
- Allergan A collaboration developing an engineered botulinum toxin molecule as a long acting novel analgesic. The partners aim to form a spin out company to progress the product through clinical trials.
- Alfa Wasserman Manufacture of a cytokine for pre-clinical studies and consistency batches to support an application for marketing authorisation from the EMEA.
Chiron An exclusive royalty-bearing licensing agreement giving Chiron access to technology for the manufacture of a multi-component meningitis B vaccine. The deal provides income whilst enabling the HPA to continue its own research and development activities in the field. - Emergent Biosolutions A two-year collaboration for the development of vaccines to prevent botulism.
- Genencor An ongoing collaboration to develop a commercially viable technology to eradicate infectious prions responsible for BSE and vCJD, for application in the decontamination of surgical instruments.
- NIAID An award for the development of In vitro and Animal Models for Emerging Diseases and Biodefence, funded with Federal funds from the US National Institute of Allergy & Infectious Diseases, under contract N01-AI30061.
- OPi Worldwide licensing of an anti-leukaemia product, Erwinase®
Partnerships that Work
Many leading organisations have already recognised the benefits of the Agency's flexible approach to business and are utilising our research, development and production expertise to generate new biotherapeutic products, vaccines and other biologically active compounds.
Given the high costs involved in setting up new research or manufacturing facilities when the value of a potential biopharmaceutical product is still unknown, it makes sound financial sense to share resources and expertise with a partner you can trust.
At the HPA we have the opportunities to make such partnerships a reality.
We believe in establishing a genuine close working relationship with our partners, enabling both parties to benefit from our patented technology and diverse range of skills.
For low risk, cost effective solutions to your biotechnology needs, talk to us about partnership opportunities.